Skip to main content
Clinical Trials/NCT03673397
NCT03673397
Completed
Not Applicable

The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression: a Randomized Controlled Trial

Oberwaid AG1 site in 1 country92 target enrollmentSeptember 24, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Oberwaid AG
Enrollment
92
Locations
1
Primary Endpoint
Change from baseline in sleep efficiency (%) at follow-up assessed by polysomnography
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The aim of this trial is to investigate the effects of a single bout of aerobic exercise on sleep in patients with depression.

Detailed Description

PRIMARY OBJECTIVE: The primary objective of this study is to evaluate whether a single bout of aerobic exercise improves sleep efficiency more than a control condition in patients with depression. SECONDARY OBJECTIVES: Secondary objectives are to assess the effects of a single bout of aerobic exercise on 1) sleep continuity, 2) sleep architecture, 3) pre-sleep arousal, 4) subjective sleep quality, 5) daytime sleepiness, 6) nocturnal blood pressure, 7) heart rate variability, and 8) the frequency and severity of adverse events. DESIGN: This will be a two-arm parallel group, randomized, outcome assessor blinded, controlled, superiority trial. According to sample size calculation a total of 92 patients will be randomized using minimization. The trial will take place in the first five days of the patients' psychosomatic in-patient rehabilitation in the clinic OBERWAID, St.Gallen, Switzerland. The study visits are scheduled is as follows: Day 0-2: Screening, inclusion, and graded exercise test to determine exercise intensity of intervention Day 3: Questionnaires for background information Night 1 (day 3-4): Baseline polysomnography and sleep related questionnaires Day 4: Randomized allocation (control or exercise condition) and performing corresponding intervention Night 2 (day 4-5): Follow-up polysomnography and sleep related questionnaires Day 5: Daytime sleepiness questionnaire

Registry
clinicaltrials.gov
Start Date
September 24, 2018
End Date
January 6, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Oberwaid AG
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Inpatient psychosomatic rehabilitation in the clinic OBERWAID, St.Gallen, Switzerland
  • Age: ≥18 and ≤65 years old
  • Primary diagnosis of depression (F32, F33) without psychotic episode according to International Statistical Classification of Diseases, 10th edition

Exclusion Criteria

  • Regular use of hypnotic agents (patients were included if no hypnotic agents were taken 2 weeks prior to study participation)
  • Factors precluding exercise testing or training
  • Use of beta-blockers (with the exception of Carvedilol \& Nebivolol)
  • Use of opioids
  • History of epilepsy
  • Restless legs syndrome defined by ≥7 points on the restless legs syndrome screening questionnaire (RLSSQ)
  • Moderate or severe sleep apnea defined by an oxygen desaturation index (ODI) ≥15 in the first polysomnography.
  • Morbid adiposity with BMI \>40

Outcomes

Primary Outcomes

Change from baseline in sleep efficiency (%) at follow-up assessed by polysomnography

Time Frame: Baseline (night 1) and follow-up (night 2)

Calculated as (total sleep time / total recording time) \* 100. Higher values represent a better outcome. A one-way ANCOVA will be computed with baseline sleep efficiency (%) and minimization factors as covariates, intervention as the independent variable, and follow-up sleep efficiency (%) as the dependent variable.

Secondary Outcomes

  • Change from baseline in number of awakenings at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in rapid eye movement sleep (% of total sleep time and minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in sleep onset latency (minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in nocturnal autonomic modulation at follow up(Baseline (night 1) and follow-up (night 2))
  • Difference in adverse events between exercise and control group(Immediately after termination of exercise intervention or control condition and after awakening from follow-up (night 2))
  • Change from baseline in stage 1 sleep (% of total sleep time and minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in stage 3 sleep (% of total sleep time and minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in non-rapid eye movement sleep (% of total sleep time and minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in stage shift index at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in wake after sleep onset (minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in light sleep (% of total sleep time and minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in rapid eye movement sleep-latency (minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in subjective sleep quality at follow-up assessed by self-rated questionnaire 'revised Schlaffragebogen A'(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in stage 2 sleep (% of total sleep time and minutes) at follow-up assessed by polysomnography(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in pre-sleep autonomic modulation at follow-up(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in post-sleep autonomic modulation at follow-up(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in nocturnal mean arterial pressure at follow-up assessed by pulse transit time (ECG, modified lead II; fingertip photoplethysmogram, single initial calibration measurement)(Baseline (night 1) and follow-up (night 2))
  • Change from baseline in subjective pre-sleep arousal at follow-up assessed by self-rated questionnaire 'Pre-Sleep Arousal Scale'(Baseline (night 1) and follow-up (night 2))
  • State sleepiness assessed by self-rated questionnaire 'Stanford Sleepiness Scale' (SSS)(Day 5 (i.e. day after night 2): at 08:00 am, 12 noon, 04:00 pm, and 08:00 pm)

Study Sites (1)

Loading locations...

Similar Trials